key: cord-0898753-nmix4cqh authors: Jin, Tianru; Liu, Mingyao title: Letter to the Editor: Comment on GLP-1-based drugs and COVID-19 treatment date: 2020-05-26 journal: Acta Pharm Sin B DOI: 10.1016/j.apsb.2020.05.006 sha: 8d222000ac5ca7337b319f353e635d707f8d88b6 doc_id: 898753 cord_uid: nmix4cqh • GLP-1R is abundantly expressed in lung epithelia and certain immune cells. • GLP-1 based drugs show “therapeutic effects” in acute and chronic lung injury models. • Clinical trial is designed in testing effect of GLP-1 analogues in treating Covid-19. • Retrospective studies should be conducted in T2D subject with Covid-19. To the Editor: The corona virus disease 2019 (COVID-19) pandemic is now spreading over 187 countries or territories, taking away hundreds to thousands of lives each day. The lack of specific and effective therapeutics is the major challenge in dealing with patients that are suffering from severe symptoms, i.e., acute respiratory distress syndrome (ARDS). Drug development with conventional drug-discovery pipelines will not meet the immediate needs. Thus, it is essential and urgent to develop repurposed therapeutics. Furthermore, type 2 diabetes (T2D) is one of the major comorbidities of COVID-19 patients who developed ARDS 1,2 . Treatment of those patients represents additional complexities. Since T2D therapeutic agents known as glucagon-like peptide-1 (GLP-1)-based drugs possess the strong anti-inflammatory effect in the lung and elsewhere, we suggest that these drugs are among potential repurposed drugs for COVID-19. We also suggest that large scale retrospective studies should be conduced, which may reveal whether administration of this type of drugs have beneficial effects on clinical outcomes of T2D patients who suffered from COVID-19, with or without ARDS. Based on available information to date, diabetes subjects are more vulnerable to SARS-CoV-2 1, 7, 8 . In diabetes patients, elevated blood glucose level can stimulate inflammasome component TxNIP, while circulation GLP-1 level could be reduced in T2D subjects. Thus, the utilization of GLP-1-based drugs could improve metabolic defects in these patients. Moreover, in case these patients are infected with SARS-CoV-2, these treatments may also ameliorate acute lung injury. It is also essential for physicians to have cross-disciplinary discussions, providing proper GLP-1based drugs for individual patient. The most serious pathological changes of COVID-19 pneumonia are ARDS, that is, excessive inflammation, with a so-called "cytokine storm", which attacks endothelial cells in multiple organs, and also attacks alveolar epithelial cells in the lung, In addition to pre-clinical animal experimentation, clinical epidemiology studies should also be considered. Up to date, there are nearly 3 million confirmed COVID-19 cases world widely. In China alone, confirmed cases are over 83,000. Since the prevalence of T2D is about 11% in China 10 , among confirmed COVID-19 cases, the incidence of T2D could be 8800 or higher. Retrospective studies to compare the clinical process and outcomes between patients who have taken GLP-1-based drugs, especially liraglutide, with those who did not receive such treatment may reveal clinical benefits if any. These studies should focus on patient's distributions from mild, moderate, severe to critically ill, especially on the development of ARDS. Moreover, one could study patient mortality, use of ECMO, days on ventilator, days in ICU, days in hospital, etc. Information gained from this kind of study may allow us to judge whether T2D patients under GLP-1-based drug treatment had better clinical outcome. Such studies will provide valuable information to the whole world in combating the pandemic; and add our knowledge in personal and precise medicine. The rapid spread of this disease with increasing mortality worldwide urges the development and discovery of new therapeutics. We propose to systemically determine the potential clinical benefits of GLP-1-related drugs via retrospective studies on COVID-19 patients with T2D in China as well as in other countries. We propose to test these drugs in coronavirus-induced acute lung injury models. Positive results from these studies could lead to clinical applications, as the pharmacokinetics, toxicology, safety of these drugs have been tested in T2D patients. Repurposing this category of medicines may provide clinically applicable medications for the urgent needs in treatment of COVID-19 disease. Both Mingyao Liu and Tianru Jin have contributed to this review manuscript composition. The authors have no conflict of interest to claim. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Understanding of COVID-19 based on current evidence GABA promotes human beta-cell proliferation and modulates glucose homeostasis Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure Diabetes and COVID-19 Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Protective effects of long pentraxin PTX3 on lung injury in a severe acute respiratory syndrome model in mice Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013